AlphaCrest Capital Management’s 10x Genomics TXG Stock Holding History

AlphaCrest Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,475	Closed	-$384K	–	1070
2022 Q3	$384K	Buy	13,475 +6,603	+96%	+$252K	0.02%	1072
2022 Q2	$311K	Buy	+6,872	New	+$357K	0.02%	1108
2022 Q1	–	Sell	-5,182	Closed	-$772K	–	1411
2021 Q4	$772K	Sell	5,182 -4,257	-45%	-$652K	0.03%	917
2021 Q3	$1.37M	Buy	9,439 +7,326	+347%	+$1.26M	0.07%	475
2021 Q2	$414K	Buy	+2,113	New	+$382K	0.02%	1019
2021 Q1	–	Sell	-2,500	Closed	-$354K	–	1308
2020 Q4	$354K	Buy	+2,500	New	+$363K	0.03%	840

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AlphaCrest Capital Management's TXG Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 13,475 shares — an estimated $384K sold.

AlphaCrest Capital Management first reported a position in TXG in Q4 2020 and held it in 6 quarters. The position peaked at $1.37M in Q3 2021. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

AlphaCrest Capital Management reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 13,475 10x Genomics shares in Q4 2022, an estimated $384K.
AlphaCrest Capital Management first reported a position in 10x Genomics in Q4 2020 and held it in 6 quarters.
AlphaCrest Capital Management's 10x Genomics position peaked at $1.37M in Q3 2021.
268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.